Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 19/20 | 0.76 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.76 |
| ▸ | OXTR | P30559 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6623184 | 0.88 | AVPR2 (0.80) | AVPR2AVPR1AOXTR | |
| SCHEMBL6625764 | 0.88 | AVPR2 (0.59) | AVPR2AVPR1AOXTR | |
| SCHEMBL6628600 | 0.87 | AVPR2 (0.81) | AVPR2AVPR1AOXTR | |
| SCHEMBL7234666 | 0.87 | AVPR2 (0.81) | AVPR2AVPR1AOXTR | |
| SCHEMBL6623630 | 0.87 | AVPR2 (0.58) | AVPR2AVPR1AOXTR | |
| SCHEMBL6623967 | 0.87 | AVPR2 (0.58) | AVPR2AVPR1AOXTR | |
| SCHEMBL6625133 | 0.86 | AVPR2 (0.56) | AVPR2AVPR1AOXTR | |
| SCHEMBL6627050 | 0.86 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL6625759 | 0.85 | AVPR2 (0.55) | AVPR2AVPR1AOXTR | |
| SCHEMBL6624978 | 0.85 | AVPR2 (0.77) | AVPR2AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000062-B1 | TRICYCLIC VASOPRESSIN AGONISTS | WYETH CORP (US) | 2004-09-22 | — | — | EP | claimed |
| US-6511974-B1 | Non-peptidic and have good oral bioavailability, specific vasopressin V2 agonists, therefore do not raise blood pressure | WYETH | 2003-01-28 | — | — | US | claimed |
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1867639-A1 | UREA DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-6831079-B1 | Oral delivery; nitrogen triheterocyclic active material, surfactant, polyethylene glycol with sucrose fatty acid esters and/or polyvinylpyrrolidone | AMERICAN CYANAMID COMPANY | 2004-12-14 | — | — | US | disclosed |
| US-6511974-B1 | Non-peptidic and have good oral bioavailability, specific vasopressin V2 agonists, therefore do not raise blood pressure | WYETH | 2003-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | AVPR2, UTS2R, GPR119 | AVPR2 1/4885AVPR1A 4/4885OXTR 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.